ArticleInvestigational new drugs2024
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.
Article in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Real-World Impact of Electronic Patient-Reported Outcomes on Early Intervention Among Older Patients With Lung Cancer: Prospective Cohort Study.JMIR cancer · 2026Article
- Trio-colored appraisal of an eco-conscious method for the determination of bisphenol A in drinking water bottles and pharmaceutical eye-drop solutions.BMC chemistry · 2026Article
- Clinical spectrum and prevalence associations of chorioretinal damage in high myopia: a retrospective cross-sectional analysis.Frontiers in medicine · 2026Article
- Cataract Management in the Modern Era: Therapeutic Advances and Unmet Needs.Current pharmaceutical design · 2026Review
- A coarse-to-fine registration method for multimodal retinal images.Scientific reports · 2025Article
- Knowledge distillation-based lightweight MobileNet model for diabetic retinopathy classification.Scientific reports · 2025Article
- Revolutionizing AMD detection Bi model CNNs and hybrid feature selection for automated grading.Scientific reports · 2025Article
- Multi-task deep learning framework combining CNN: vision transformers and PSO for accurate diabetic retinopathy diagnosis and lesion localization.Scientific reports · 2025Article
- Modeling and Design of Chitosan-PCL Bi-Layered Microspheres for Intravitreal Controlled Release.Pharmaceutics · 2025Article
- Regulation of toll-like receptor signaling pathways in age-related eye disease: from mechanisms to targeted therapeutics.Inflammopharmacology · 2025Review
- High-Sensitivity C-Reactive Protein and its Association with Diabetic Retinopathy: A Cross-sectional Study.Archives of Iranian medicine · 2025Article
- Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery.Current treatment options in oncology · 2025Review
- Resolvin D1 alleviates lipopolysaccharide-inducedBioImpacts : BI · 2025Article
- Exosomes-derived mesenchymal stem cells in corneal regeneration: Properties and challenges.BioImpacts : BI · 2025Review
- Microbiota and Cytokine Modulation: Innovations in Enhancing Anticancer Immunity and Personalized Cancer Therapies.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The aim of this study was to investigate the clinical characteristics of pembrolizumab-induced uveitis and to provide reference for prevention, diagnosis and treatment. We collected studies related to pembrolizumab-induced uveitis by searching databases for retrospective analysis until April 30, 2024. The median age of the 31 patients was 63 years (range 7, 82), and the median duration of uveitis onset was 12 weeks (range 0.4, 108). Decreased vision (41.9%) and blurred vision (25.8%) were the most common complaints. Uveitis can be manifested as Vogt-Koyanagi-Harada disease-like uveitis (22.6%) and Birdshot uveitis (6.5%). Uveitis mainly affects both eyes and is related to anterior uveitis (35.5%), panuveitis (25.8%) and posterior uveitis (19.4%). Patients receiving topical steroid drops, systemic steroids, and withdrawal of pembrolizumab significantly improved symptoms at a median time of 4 weeks (range 2, 16). The possibility of uveitis should be considered when patients are treated with pembrolizumab and experience eye symptoms such as blurred vision and decreased vision. Depending on the severity of uveitis, treatment with topical and systemic steroids may be selected.
Indexed as
Identifiers
39141261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.